Publications by authors named "Nicolas Whenham"

Claim this Profile
S
SMART Syndrome: Case Report and Review of the Literature.
Christophe Dossin, Dario Di Perri, Nicolas Whenham, Anna Paola Bocchio, Idil Gunes Tatar

J Belg Soc Radiol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
Georges Chehade, Tévi Morel Lawson, Julie Lelotte, Lina Daoud, Dario Di Perri, Nicolas Whenham

Acta Neurochir (Wien)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Martin van den Bent, Marica Eoli, Juan Manuel Sepulveda, Marion Smits, Annemiek Walenkamp, Nicolas Whenham

Neuro Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central diabetes insipidus induced by temozolomide: A report of two cases.
Cédric Mahiat, Antoine Capes, Thierry Duprez, Nicolas Whenham, Lionel Duck

J Oncol Pharm Pract· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Paul M J Clement, Linda Dirven, Marica Eoli, Juan M Sepulveda-Sanchez, Annemiek M E Walenkamp, Nicolas Whenham

Eur J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Martin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, Marion Smits, Annemiek Walenkamp, Nicolas Whenham

Neuro Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
Emmanuel Costa, Tévi M Lawson, Julie Lelotte, Edward Fomekong, R Geraldo Vaz, Nicolas Whenham

J Neurosurg Sci· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Jean-Pascal Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Nicolas Whenham

Oncologist· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Ahmad Awada, Thierry Gil, Nicolas Whenham, Julie Van Hamme, Tatiana Besse-Hammer

J Clin Pharmacol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
Nicolas Whenham, Véronique D'Hondt, Martine J Piccart

Clin Breast Cancer· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis